Plum Creek

Plum Creek Therapeutics is a preclinical-stage biotechnology company focused on the discovery and development of novel therapies targeting the 'dark matter' of the human genome, specifically non-coding RNA (ncRNA). Founded by Dr. Claes Wahlestedt, a pioneer in RNA biology, the company leverages a proprietary platform to identify small molecules and oligonucleotides that can modulate natural antisense transcripts and RNA-binding proteins. Their research aims to unlock new regulatory pathways for treating complex diseases that have remained undruggable by traditional protein-centric approaches. The company's primary therapeutic focus areas include oncology and neurodegenerative disorders, such as Alzheimer's disease. Plum Creek Therapeutics is currently advancing a pipeline of early-stage candidates designed to restore healthy gene expression patterns through precise RNA modulation.